2nd Next Generation RNA Therapeutics Summit
Bringing Next Generation RNA Therapies to Patients Faster
Newsletters and Deep Dive digital magazine
Bringing Next Generation RNA Therapies to Patients Faster
Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myer
Takeda has made a strong play for a stake in the Alzheimer’s disease market, paying $100 million upfront for an option on AC Immune’s amyloid-targeting immunotherapy.
Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.
In this edition of Deep Dive, Unpacking complex choreography in the biologics patent dance, Alexion examines the urgent need for accelerated access programmes for rare disease treatments, and Putna
It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.
We are living in an era of unprecedented advances in cancer treatments with transformative therapies being regularly approved.
The commercial success of cell therapies is continuing to grow!
The 2nd mRNA Quality Control & Compliance Summit 2024 returns this June 25-27 (Boston, MA), as the sole industry-centred forum dedicated to showcasing technical data and though
Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox